Devyser and QIAGEN collaborate on pre-analytical workflow for fetal RHD screening
Fetal derived cell-free DNA (cfDNA) is a key analyte for determining fetal RHD status in plasma...
News | May 8, 2023
Devyser winner of Swecare Export Awards 2023News | April 24, 2023
Devyser enters agreement with Thermo Fisher Scientific for commercialization of Devyser’s post-transplant NGS productsNews | March 1, 2023
Devyser launches first IVDR-certified product
Approval of Devyser’s RHD product in Canada
Devyser is today announcing that its product for non-invasive fetal RHD testing has been granted...
Devyser Diagnostics AB publishes quarterly report for the period January to March 2023
“The first quarter of the year saw continued strong growth, record gross margin and the launching...
Devyser’s clinical laboratory in Atlanta receives CLIA certification
Devyser is today announcing that the company’s clinical testing laboratory in Roswell in Atlanta,...